Update on cancer prevention research in the United States and China: The 2009 China - U.S. forum on frontiers of cancer research

Cancer Prevention Research

Volumn 3, Issue 12, 2010, Pages 1630-1637

  Bode, Ann M ^a   Cao, Ya ^b   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Central South University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; DNA METHYLTRANSFERASE INHIBITOR; DUTASTERIDE; EFLORNITHINE; FINASTERIDE; GAMMA TOCOPHEROL; HISTONE DEACETYLASE INHIBITOR; KAEMPFEROL; PLANT MEDICINAL PRODUCT; RALOXIFENE; SILIBININ; SULINDAC; TAMOXIFEN;

BREAST CANCER; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CARDIOVASCULAR DISEASE; CHINA; COLON ADENOMA; COLON CANCER; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; HEALTH CARE ACCESS; HEALTH CARE POLICY; HUMAN; IMMUNIZATION; LIFESTYLE MODIFICATION; LIVER CANCER; LOW DRUG DOSE; NATIONAL HEALTH ORGANIZATION; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION CARCINOGENESIS; SILYBUM MARIANUM; SKIN CARCINOGENESIS; SMOKING CESSATION; UNITED STATES;

BIOMEDICAL RESEARCH; CHINA; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; UNITED STATES;

EID: 78650373746     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-10-0107     Document Type: Conference Paper

References (85)

1. Fan YG, Hu P, Jiang Y, Chang RS, Yao SX, Wang W, et al. Association between sputum atypia and lung cancer risk in an occupational cohort in Yunnan, China. Chest 2009;135:778-85.
2. Wattenberg LW. Chemoprophylaxis of carcinogenesis: a review. Cancer Res 1966;26:1520-6.
3. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
4. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985;45:1-8.
5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-7.
6. Lee L. The current state of public health in China. Annu Rev Public Health 2004;25:327-39.
7. Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst 1981;66:1191-308.
8. Greenwald P, Dunn BK. Landmarks in the history of cancer epidemiology. Cancer Res 2009;69:2151-62.
9. Garcia M, Jemal A, Ward EM, et al. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society; 2007.
10. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38.
11. Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005;97:1652-62.
12. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
13. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
14. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res 2010;3:696-706.
15. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24.
16. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2002 ;362:1192-202.
17. Albanes D, Heinonen OP, Taylor PR, Virtamo J, Edwards BK, Rautalahti M, et al. Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70.
18. Omenn GS, Goodman G, Thornquist M, Grizzle J, Rosenstock L, Barnhart S, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res 1994;54:2038s-43s. (Pubitemid 24132171)
19. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009;301:39-51.
20. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst 2006;98:1767-76.
21. Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. J Natl Cancer Inst 2007;99:1534-43. (Pubitemid 351767234)
22. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593-6.
23. Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-52.
24. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
25. Meyskens FL Jr, McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
26. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Malone WA, Boone CW, et al. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J Nutr 2000;130:467S-71S.
27. Kelloff GJ, Lieberman R, Steele VE, Boone CW, Lubet RA, Kopelovich L, et al. Agents, biomarkers, and cohorts for chemopreventive agent development in prostate cancer. Urology 2001;57:46-51. (Pubitemid 32532385)
28. Steele VE. Current mechanistic approaches to the chemoprevention of cancer. J Biochem Mol Biol 2003;36:78-81. (Pubitemid 36836259)
29. Steele VE, Kelloff GJ. Development of cancer chemopreventive drugs based on mechanistic approaches. Mutat Res 2005;591:16-23.
30. Lippman SM, Heymach JV. The convergent development of molecular-targeted drugs for cancer treatment and prevention. Clin Cancer Res 2007;13:4035-41.
31. Huang P, Woolson RF, O'Brien PC. A rank-based sample size method for multiple outcomes in clinical trials. Stat Med 2008;27:3084-104.
32. Bode AM, Dong Z. Cancer prevention research - then and now. Nat Rev Cancer 2009;9:508-16.
33. Bode AM, Dong Z. Signal transduction molecules as targets for cancer prevention. Sci Signal 2009;2:mr2.
34. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003;3:768-80.
35. Kundu JK, Surh YJ. Chemoprevention with dietary phytochemicals: redox sensitive transcription factors as prime targets. Phytochem Rev 2009;8:333-47.
36. Jeong CH, Bode AM, Pugliese A, Cho YY, Kim HG, Shim JH, et al. [6]-Gingerol suppresses colon cancer growth by targeting leukotriene A4 hydrolase. Cancer Res 2009;69:5584-91.
37. Kang NJ, Lee KW, Shin BJ, Jung SK, Hwang MK, Bode AM, et al. Caffeic acid, a phenolic phytochemical in coffee, directly inhibits Fyn kinase activity and UVB-induced COX-2 expression. Carcinogenesis 2009;30:321-30.
38. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: United they work, divided they fail. Cancer Prev Res 2009;2:514-7.
39. Zykova TA, Zhu F, Zhai X, Ma WY, Ermakova SP, Lee KW, et al. Resveratrol directly targets COX-2 to inhibit carcinogenesis. Mol Carcinog 2008.
40. Shim JH, Choi HS, Pugliese A, Lee SY, Chae JI, Choi BY, et al. (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J Biol Chem 2008;283:28370-9.
41. Rogozin EA, Lee KW, Kang NJ, Yu H, Nomura M, Miyamoto K, et al. Inhibitory effects of caffeine analogues on neoplastic transformation: structure-activity relationship. Carcinogenesis 2008;29:1228-34. (Pubitemid 351958703)
42. Lee KW, Kang NJ, Rogozin EA, Oh SM, Heo YS, Pugliese A, et al. The resveratrol analogue 3,5,30,40,50-pentahydroxy-trans-stilbene inhibits cell transformation via MEK. Int J Cancer 2008;123:2487-96.
43. Lee KW, Kang NJ, Heo YS, Rogozin EA, Pugliese A, Hwang MK, et al. Raf and MEK protein kinases are direct molecular targets for the chemopreventive effect of quercetin, a major flavonol in red wine. Cancer Res 2008;68:946-55. (Pubitemid 351206774)
44. Kang NJ, Lee KW, Lee DE, Rogozin EA, Bode AM, Lee HJ, et al. Cocoa procyanidins suppress transformation by inhibiting mitogen-activated protein kinase kinase. J Biol Chem 2008;283:20664-73.
45. Kang NJ, Lee KW, Kwon JY, Hwang MK, Rogozin EA, Heo YS, et al. Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling. Cancer Prev Res 2008;1:522-31.
46. He Z, Tang F, Ermakova S, Li M, Zhao Q, Cho YY, et al. Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation. Mol Carcinog 2008;47:172-83. (Pubitemid 351409338)
47. Cho YY, Yao K, Pugliese A, Malakhova ML, Bode AM, Dong Z. A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res 2009;69:4398-406.
48. Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, et al. Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice. Int J Cancer 2009;124:1693-9.
49. Ju J, Hao X, Lee MJ, Lambert JD, Lu G, Xiao H, et al. A gamma-tocopherol-rich mixture of tocopherols inhibits colon inflammation and carcinogenesis in azoxymethane and dextran sulfate sodium-treated mice. Cancer Prev Res 2009;2:143-52.
50. Lambert JD, Lu G, Lee MJ, Hu J, Ju J, Yang CS. Inhibition of lung cancer growth in mice by dietary mixed tocopherols. Mol Nutr Food Res 2009;53:1030-5.
51. Lee HJ, Ju J, Paul S, So JY, DeCastro A, Smolarek A, et al. Mixed tocopherols prevent mammary tumorigenesis by inhibiting estrogen action and activating PPAR-gamma. Clin Cancer Res 2009;15:4242-9.
52. Suh N, Paul S, Lee HJ, Ji Y, Lee MJ, Yang CS, et al. Mixed tocopherols inhibit N-methyl-N-nitrosourea-induced mammary tumor growth in rats. Nutr Cancer 2007;59:76-81. (Pubitemid 47549784)
53. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res 2008;68:2043-50. (Pubitemid 351416592)
54. Velmurugan B, Singh RP, Tyagi A, Agarwal R. Inhibition of azoxymethane-induced colonic aberrant crypt foci formation by silibinin in male Fisher 344 rats. Cancer Prev Res 2008;1:376-84.
55. Kaur M, Velmurugan B, Tyagi A, Deep G, Katiyar S, Agarwal C, et al. Silibinin suppresses growth and induces apoptotic death of human colorectal carcinoma LoVo cells in culture and tumor xenograft. Mol Cancer Ther 2009;8:2366-74.
56. Rao CV, Steele VE, Swamy MV, Patlolla JM, Guruswamy S, Kopelovich L. Inhibition of azoxymethane-induced colorectal cancer by CP-31398, a TP53 modulator, alone or in combination with low doses of celecoxib in male F344 rats. Cancer Res 2009;69:8175-82.
57. Guruswamy S, Rao CV. Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. Int J Oncol 2009;35:1037-43.
58. Guruswamy S, Rao CV. Multi-target approaches in colon cancer chemoprevention based on systems biology of tumor cell-signaling. Gene Regul Syst Bio 2008;2:163-76. (Pubitemid 351658732)
59. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006;5:1530-8. (Pubitemid 44070490)
60. Stan SD, Singh SV. Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells. Clin Cancer Res 2009;15:4895-903.
61. Xiao D, Zeng Y, Hahm ER, Kim YA, Ramalingam S, Singh SV. Diallyl trisulfide selectively causes Bax- and Bak-mediated apoptosis in human lung cancer cells. Environ Mol Mutagen 2009;50:201-12.
62. Bommareddy A, Hahm ER, Xiao D, Powolny AA, Fisher AL, Jiang Y, et al. Atg5 regulates phenethyl isothiocyanate-induced autophagic and apoptotic cell death in human prostate cancer cells. Cancer Res 2009;69:3704-12.
63. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE 2003 ;2003:RE2.
64. Zheng D, Bode AM, Zhao Q, Cho YY, Zhu F, Ma WY, et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008;68:3992-8.
65. Bode AM, Cho YY, Zheng D, Zhu F, Ericson ME, Ma WY, et al. Transient receptor potential type vanilloid 1 suppresses skin carcinogenesis. Cancer Res 2009;69:905-13.
66. Choi HS, Bode AM, Shim JH, Lee SY, Dong Z. JNK1 Phosphorylates Myt1 to Prevent UVA-Induced Skin Cancer. Mol Cell Biol 2009;29:2168-80.
67. She QB, Chen N, Bode AM, Flavell RA, Dong Z. Deficiency of c-Jun-NH (2)-terminal kinase-1 in mice enhances skin tumor development by 12- O-tetradecanoylphorbol-13-acetate. Cancer Res 2002;62:1343-8.
68. Chen N, She QB, Bode AM, Dong Z. Differential gene expression profiles of Jnk1- and Jnk2-deficient murine fibroblast cells. Cancer Res 2002;62:1300-4. (Pubitemid 34407782)
69. Chen N, Nomura M, She QB, Ma WY, Bode AM, Wang L, et al. Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res 2001;61:3908-12.
70. Kim DJ, Angel JM, Sano S, DiGiovanni J. Constitutive activation and targeted disruption of signal transducer and activator of transcription 3 (Stat3) in mouse epidermis reveal its critical role in UVB-induced skin carcinogenesis. Oncogene 2009;28:950-60.
71. Kim DJ, Kataoka K, Rao D, Kiguchi K, Cotsarelis G, DiGiovanni J. Targeted disruption of stat3 reveals a major role for follicular stem cells in skin tumor initiation. Cancer Res 2009;69:7587-94.
72. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res 2008;1:65-76.
73. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007;6:1-12. (Pubitemid 46206663)
74. Zeng X, Yee D. Insulin-like growth factors and breast cancer therapy. Adv Exp Med Biol 2007;608:101-12.
75. Zeng X, Sachdev D, Zhang H, Gaillard-Kelly M, Yee D. Sequencing of type I insulin-like growth factor receptor inhibition affects chemotherapy response in vitro and in vivo. Clin Cancer Res 2009;15:2840-9.
76. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2007;96 Suppl:R7-10.
77. Young MR, Yang HS, Colburn NH. Promising molecular targets for cancer prevention: AP-1, NF-kappa B and Pdcd4. Trends Mol Med 2003;9:36-41.
78. Matthews CP, Birkholz AM, Baker AR, Perella CM, Beck GR Jr, Young MR, et al. Dominant-negative activator protein 1 (TAM67) targets cyclooxygenase-2 and osteopontin under conditions in which it specifically inhibits tumorigenesis. Cancer Res 2007;67:2430-8.
79. Wei Q, Jiang H, Matthews CP, Colburn NH. Sulfiredoxin is an AP-1 target gene that is required for transformation and shows elevated expression in human skin malignancies. Proc Natl Acad Sci USA 2008;105:19738-43.
80. Kang MI, Henrich CJ, Bokesch HR, Gustafson KR, McMahon JB, Baker AR, et al. A selective small-molecule nuclear factor-kappaB inhibitor from a high-throughput cell-based assay for "activator protein-1 hits". Mol Cancer Ther 2009;8:571-81.
81. Yasuda M, Nishizawa T, Ohigashi H, Tanaka T, Hou DX, Colburn NH, et al. Linoleic acid metabolite suppresses skin inflammation and tumor promotion in mice: possible roles of programmed cell death 4 induction. Carcinogenesis 2009;30:1209-16.
82. Su H, Yang JR, Xu T, et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res 2009;69:1135-42.
83. Xiong Y, Fang JH, Yun JP, Yang J, Zhang Y, Jia WH, et al. Effects of MicroRNA-29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma. Hepatology 2009;51:836-45.
84. Xu T, Zhu Y, Xiong Y, Ge YY, Yun JP, Zhuang SM. MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology 2009;50:113-21.
85. Tao Q, Chan AT. Nasopharyngeal carcinoma: molecular pathogenesis and therapeutic developments. Expert Rev Mol Med 2007;9:1-24. (Pubitemid 47398642)